Morgan Stanley: Maintains "Shareholding" rating on HANSOH PHARMA (03692) with a Target Price of 24 Hong Kong dollars.

HANSOH PHARMA announced the signing of a global exclusive licensing agreement with Merck, granting them global exclusive rights to develop, manufacture, and commercialize the preclinical oral small molecule GLP-1 receptor agonist HS-10535.

Zhitong Finance22:22 ET

Goldman Sachs: Initiates coverage on HANSOH PHARMA (03692) with a "Buy" rating and a Target Price of HKD 20.97.

Goldman Sachs believes that HANSOH PHARMA can jointly promote or independently commercialize this product in mainland China and Hong Kong and Macau.

Zhitong Finance20:48 ET

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Simply Wall St17:58 ET

Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug

Yahoo Finance13:05 ET

Valued at 2 billion dollars! HANSOH PHARMA grants Merck exclusive global licensing rights for the oral weight loss drug.

① Merck and HANSOH PHARMA in China signed a $2 billion agreement to develop and sell the experimental oral weight loss drug HS-10535, which has effects similar to Wegovy and Zepbound; ② HANSOH PHARMA granted Merck global exclusive licensing rights for HS-10535, receiving an initial payment of $0.112 billion and up to $1.9 billion in milestone payments, along with royalties based on product sales.

cls.cnDec 18 09:08 ET

Viking Shares Tumble After Merck Inks Deal With Hansoh Pharma

InvestingDec 18 08:14 ET